RNA BIOCLIN
Board
1 director, since incorporationManager
since 20-04-2015
term without a fixed end
listed in the 2025 annual accounts, filed on 30-09-2026
Mandates through the years
1 name, the dashed line is todayManager
Board
Mandates as a list
-
- Manager, from 20-04-2015 to date
Control
100%
This company
RNA BIOCLIN
Equity €175,530
Profit €90,311 in 2025
Capital
- Contribution
- €18,600
- Shares
- 100
- Contribution per share
- €186
- Equity per share
- €1,755 in 2025
- Source
- 2025 annual accounts
Articles of association
- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimiteddeed of 16-02-2024 (in French)
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Second Tuesday of Maydeed of 22-04-2015 (in French)
Capital transactions
Shareholders according to the deeds
At incorporation
deed of 22-04-2015 ↗
- 100 shares (100%) · €18,600
Capital over time
- 16-02-2024 Converted to unavailable equity · €20,460
- 22-04-2015 Incorporation · €18,600 · 100 shares